 Seth Furgeson
Concepts (162)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ureteral Obstruction | 3 | 2021 | 59 | 1.530 |
Why?
| | Kidney | 5 | 2023 | 1357 | 1.270 |
Why?
| | Group IV Phospholipases A2 | 2 | 2017 | 46 | 1.190 |
Why?
| | Myocytes, Smooth Muscle | 6 | 2018 | 238 | 1.060 |
Why?
| | Muscle, Smooth, Vascular | 6 | 2019 | 457 | 1.020 |
Why?
| | PTEN Phosphohydrolase | 7 | 2019 | 143 | 1.010 |
Why?
| | Renal Insufficiency, Chronic | 2 | 2022 | 590 | 0.960 |
Why?
| | Lipoxygenase Inhibitors | 2 | 2021 | 36 | 0.880 |
Why?
| | Arachidonate 12-Lipoxygenase | 1 | 2021 | 13 | 0.830 |
Why?
| | Arachidonate 15-Lipoxygenase | 1 | 2021 | 16 | 0.830 |
Why?
| | Nephritis | 1 | 2021 | 30 | 0.820 |
Why?
| | Fibrosis | 7 | 2021 | 483 | 0.760 |
Why?
| | Inflammation Mediators | 2 | 2021 | 502 | 0.730 |
Why?
| | Kidney Tubules | 2 | 2019 | 128 | 0.700 |
Why?
| | Cell Dedifferentiation | 2 | 2016 | 30 | 0.660 |
Why?
| | Metabolome | 1 | 2021 | 296 | 0.660 |
Why?
| | Connective Tissue Growth Factor | 1 | 2017 | 21 | 0.620 |
Why?
| | Vascular Endothelial Growth Factor C | 1 | 2017 | 16 | 0.620 |
Why?
| | Nephrosclerosis | 1 | 2016 | 6 | 0.580 |
Why?
| | Renal Dialysis | 2 | 2013 | 378 | 0.580 |
Why?
| | Kidney Diseases | 2 | 2017 | 442 | 0.570 |
Why?
| | Energy Metabolism | 1 | 2021 | 767 | 0.560 |
Why?
| | Bone Marrow | 1 | 2017 | 255 | 0.560 |
Why?
| | Optical Imaging | 1 | 2016 | 56 | 0.550 |
Why?
| | Angiotensin II | 2 | 2019 | 107 | 0.520 |
Why?
| | Cytokines | 2 | 2021 | 1900 | 0.520 |
Why?
| | Kidney Failure, Chronic | 2 | 2013 | 516 | 0.510 |
Why?
| | Retinoid X Receptors | 1 | 2014 | 38 | 0.500 |
Why?
| | Microscopy, Fluorescence | 1 | 2016 | 412 | 0.500 |
Why?
| | Hypertension | 1 | 2022 | 1203 | 0.450 |
Why?
| | Uremia | 1 | 2013 | 18 | 0.450 |
Why?
| | Acidosis | 1 | 2013 | 86 | 0.410 |
Why?
| | Epithelial Cells | 2 | 2018 | 963 | 0.400 |
Why?
| | Inflammation | 2 | 2014 | 2571 | 0.400 |
Why?
| | Pseudohypoaldosteronism | 1 | 2010 | 2 | 0.390 |
Why?
| | Polycystic Kidney Diseases | 2 | 2023 | 55 | 0.380 |
Why?
| | Tunica Intima | 2 | 2010 | 78 | 0.380 |
Why?
| | Carotid Artery Injuries | 1 | 2010 | 42 | 0.360 |
Why?
| | Gene Expression | 1 | 2014 | 1492 | 0.340 |
Why?
| | Peritonitis | 1 | 2009 | 79 | 0.330 |
Why?
| | Cell Proliferation | 4 | 2016 | 2275 | 0.330 |
Why?
| | Drug Resistance, Bacterial | 1 | 2009 | 155 | 0.320 |
Why?
| | Mice, Knockout | 5 | 2021 | 2680 | 0.320 |
Why?
| | Peritoneal Dialysis | 1 | 2009 | 85 | 0.320 |
Why?
| | Polycystic Kidney, Autosomal Dominant | 2 | 2023 | 209 | 0.310 |
Why?
| | Vascular Remodeling | 2 | 2019 | 152 | 0.300 |
Why?
| | Mice, Inbred C57BL | 4 | 2021 | 4914 | 0.290 |
Why?
| | Disease Models, Animal | 6 | 2021 | 3730 | 0.280 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2008 | 301 | 0.270 |
Why?
| | Mice | 11 | 2023 | 15528 | 0.270 |
Why?
| | Phenotype | 4 | 2021 | 3004 | 0.260 |
Why?
| | Animals | 14 | 2023 | 33399 | 0.260 |
Why?
| | Chlorthalidone | 1 | 2022 | 7 | 0.220 |
Why?
| | Signal Transduction | 6 | 2019 | 4713 | 0.210 |
Why?
| | Proto-Oncogene Proteins c-akt | 3 | 2014 | 420 | 0.200 |
Why?
| | Cellular Microenvironment | 1 | 2021 | 79 | 0.200 |
Why?
| | Leukocytes | 1 | 2021 | 290 | 0.190 |
Why?
| | Nephrology | 1 | 2020 | 50 | 0.180 |
Why?
| | Anti-Bacterial Agents | 1 | 2009 | 1517 | 0.180 |
Why?
| | Chemokine CXCL12 | 2 | 2011 | 80 | 0.180 |
Why?
| | Cells, Cultured | 5 | 2019 | 4081 | 0.170 |
Why?
| | Receptors, Leukotriene | 1 | 2019 | 13 | 0.170 |
Why?
| | Rats | 5 | 2019 | 5394 | 0.170 |
Why?
| | Arachidonate 5-Lipoxygenase | 1 | 2019 | 45 | 0.170 |
Why?
| | Antihypertensive Agents | 1 | 2022 | 438 | 0.160 |
Why?
| | Lymphangiogenesis | 1 | 2017 | 23 | 0.160 |
Why?
| | Intracellular Signaling Peptides and Proteins | 2 | 2010 | 404 | 0.150 |
Why?
| | Adaptive Immunity | 1 | 2018 | 161 | 0.150 |
Why?
| | Vascular Diseases | 1 | 2019 | 241 | 0.150 |
Why?
| | Arachidonic Acid | 1 | 2016 | 122 | 0.140 |
Why?
| | Actins | 2 | 2018 | 404 | 0.140 |
Why?
| | Coronary Vessels | 1 | 2018 | 233 | 0.140 |
Why?
| | Cardiovascular Diseases | 1 | 2008 | 1802 | 0.140 |
Why?
| | Dinoprostone | 1 | 2016 | 193 | 0.140 |
Why?
| | Gene Silencing | 1 | 2016 | 177 | 0.130 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2017 | 369 | 0.130 |
Why?
| | Cadherins | 1 | 2016 | 186 | 0.130 |
Why?
| | Macrophages | 1 | 2021 | 1324 | 0.120 |
Why?
| | Tetrahydronaphthalenes | 1 | 2014 | 32 | 0.120 |
Why?
| | Cell Line | 2 | 2018 | 2707 | 0.120 |
Why?
| | Chemokine CCL2 | 1 | 2014 | 126 | 0.120 |
Why?
| | Atherosclerosis | 1 | 2018 | 346 | 0.120 |
Why?
| | Microfilament Proteins | 1 | 2014 | 134 | 0.120 |
Why?
| | Humans | 12 | 2023 | 119032 | 0.120 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2014 | 286 | 0.120 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2018 | 702 | 0.110 |
Why?
| | PPAR gamma | 1 | 2014 | 189 | 0.110 |
Why?
| | Calcium-Binding Proteins | 1 | 2014 | 217 | 0.110 |
Why?
| | MAP Kinase Signaling System | 1 | 2014 | 293 | 0.110 |
Why?
| | Heart-Assist Devices | 1 | 2018 | 485 | 0.100 |
Why?
| | Promoter Regions, Genetic | 1 | 2016 | 1158 | 0.100 |
Why?
| | Serum Response Factor | 1 | 2011 | 31 | 0.100 |
Why?
| | Male | 8 | 2021 | 57818 | 0.100 |
Why?
| | Neointima | 1 | 2011 | 12 | 0.100 |
Why?
| | WNK Lysine-Deficient Protein Kinase 1 | 1 | 2010 | 1 | 0.100 |
Why?
| | Epithelial Sodium Channels | 1 | 2010 | 12 | 0.100 |
Why?
| | RNA Interference | 2 | 2010 | 460 | 0.100 |
Why?
| | Phosphatidylinositol 3-Kinases | 2 | 2010 | 343 | 0.100 |
Why?
| | Minor Histocompatibility Antigens | 1 | 2010 | 41 | 0.090 |
Why?
| | Internship and Residency | 1 | 2020 | 1006 | 0.090 |
Why?
| | Gene Expression Regulation | 1 | 2019 | 2446 | 0.090 |
Why?
| | Potassium Channels | 1 | 2010 | 123 | 0.090 |
Why?
| | Virginiamycin | 1 | 2009 | 3 | 0.090 |
Why?
| | Linezolid | 1 | 2009 | 16 | 0.090 |
Why?
| | Daptomycin | 1 | 2009 | 19 | 0.090 |
Why?
| | Oxazolidinones | 1 | 2009 | 14 | 0.090 |
Why?
| | Acetamides | 1 | 2009 | 26 | 0.090 |
Why?
| | Rats, Sprague-Dawley | 1 | 2014 | 2478 | 0.080 |
Why?
| | Autocrine Communication | 1 | 2008 | 42 | 0.080 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2010 | 369 | 0.070 |
Why?
| | Hypoxia | 1 | 2013 | 963 | 0.070 |
Why?
| | Sympathetic Nervous System | 1 | 2008 | 171 | 0.070 |
Why?
| | Immunotherapy | 2 | 2018 | 493 | 0.070 |
Why?
| | NF-kappa B | 1 | 2010 | 670 | 0.070 |
Why?
| | Staphylococcus aureus | 1 | 2009 | 394 | 0.070 |
Why?
| | Staphylococcal Infections | 1 | 2009 | 346 | 0.060 |
Why?
| | Mutation | 2 | 2018 | 3457 | 0.060 |
Why?
| | MicroRNAs | 1 | 2011 | 637 | 0.060 |
Why?
| | Hypertension, Pulmonary | 2 | 2013 | 1794 | 0.060 |
Why?
| | Mice, Transgenic | 2 | 2019 | 2025 | 0.060 |
Why?
| | Cell Movement | 1 | 2008 | 897 | 0.060 |
Why?
| | Stem Cells | 1 | 2008 | 559 | 0.060 |
Why?
| | Hyperplasia | 2 | 2018 | 170 | 0.060 |
Why?
| | B7-1 Antigen | 1 | 2023 | 69 | 0.060 |
Why?
| | Mycobacterium bovis | 1 | 2003 | 11 | 0.060 |
Why?
| | BCG Vaccine | 1 | 2003 | 25 | 0.060 |
Why?
| | Mycobacterium Infections | 1 | 2003 | 61 | 0.050 |
Why?
| | Cell Differentiation | 3 | 2018 | 1753 | 0.050 |
Why?
| | B7-H1 Antigen | 1 | 2023 | 144 | 0.050 |
Why?
| | Combined Modality Therapy | 1 | 2023 | 1167 | 0.050 |
Why?
| | Prognosis | 1 | 2008 | 3443 | 0.040 |
Why?
| | Disease Progression | 2 | 2018 | 2490 | 0.040 |
Why?
| | Focus Groups | 1 | 2020 | 387 | 0.040 |
Why?
| | Mice, Knockout, ApoE | 1 | 2018 | 9 | 0.040 |
Why?
| | Career Choice | 1 | 2020 | 192 | 0.040 |
Why?
| | TRPP Cation Channels | 1 | 2018 | 63 | 0.040 |
Why?
| | Fellowships and Scholarships | 1 | 2020 | 250 | 0.040 |
Why?
| | Blotting, Western | 1 | 2019 | 1195 | 0.040 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2018 | 156 | 0.040 |
Why?
| | Flow Cytometry | 1 | 2019 | 1085 | 0.030 |
Why?
| | Female | 3 | 2018 | 61588 | 0.030 |
Why?
| | RNA | 1 | 2019 | 833 | 0.030 |
Why?
| | Endothelium, Vascular | 1 | 2018 | 907 | 0.020 |
Why?
| | Adult | 3 | 2023 | 31525 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-fos | 1 | 2011 | 193 | 0.020 |
Why?
| | Bone Marrow Cells | 1 | 2011 | 273 | 0.020 |
Why?
| | Models, Animal | 1 | 2011 | 363 | 0.020 |
Why?
| | Hematopoietic Stem Cells | 1 | 2011 | 359 | 0.020 |
Why?
| | Receptors, CXCR4 | 1 | 2008 | 81 | 0.020 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2008 | 246 | 0.020 |
Why?
| | Arteries | 1 | 2008 | 250 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2008 | 564 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2013 | 2674 | 0.020 |
Why?
| | Heart Failure | 1 | 2018 | 1968 | 0.020 |
Why?
| | Up-Regulation | 1 | 2008 | 872 | 0.020 |
Why?
| | Aged | 2 | 2018 | 19661 | 0.010 |
Why?
| | Phosphorylation | 1 | 2008 | 1634 | 0.010 |
Why?
| | Hepatitis | 1 | 2003 | 46 | 0.010 |
Why?
| | Carcinoma, Transitional Cell | 1 | 2003 | 58 | 0.010 |
Why?
| | Middle Aged | 2 | 2018 | 27627 | 0.010 |
Why?
| | Urinary Bladder Neoplasms | 1 | 2003 | 211 | 0.010 |
Why?
| | Pneumonia | 1 | 2003 | 592 | 0.010 |
Why?
|
|
Furgeson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|